Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

Start Date01 May 2026

Sponsor / Collaborator

University of Colorado Denver

[+1]

NCT06913023

/ Not yet recruitingPhase 2/3IIT

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

Start Date05 Jan 2026

Sponsor / Collaborator

University Health Network

NCT06977438

/ Not yet recruitingPhase 4IIT

Promoting Healthy Children and Youth

The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive (26+ hours) of HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.

Start Date01 Jan 2026

Sponsor / Collaborator

University of Minnesota

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

299

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)

Article

Author: Zhao, Zhenxiang ; Alvarez, Sara ; Michalak, Wojciech ; Faurby, Mads ; Fitch, Angela

BACKGROUND:

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medical costs and healthcare resource utilization (HCRU) remains unknown.

AIMS:

To compare all-cause medical costs and HCRU among patients with ov/ob and ASCVD treated with semaglutide 2.4 mg versus semaglutide-untreated controls.

MATERIALS AND METHODS:

This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date. Patients in the semaglutide 2.4 mg cohort initiated treatment after 4 June 2021 and stayed adherent. Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU. Medical costs and HCRU were compared using generalized linear models.

RESULTS:

770 semaglutide 2.4 mg-treated patients and 3,080 controls were included. In the year following treatment initiation, semaglutide 2.4 mg was associated with 22% lower mean medical costs versus controls (-$4,639 per patient per year [PPPY]; cost ratio = 0.78, 95% confidence interval [CI] 0.67, 0.89). This difference is mainly due to lower inpatient costs with semaglutide 2.4 mg, which were 65% lower than controls (-$3,593; cost ratio = 0.35 [95% CI 0.21, 0.49]), along with a 48% lower inpatient visit rate (0.08 vs. 0.15; rate ratio = 0.52 [95% CI 0.34, 0.70]).

LIMITATIONS:

Limitations inherent to retrospective claims analyses apply to this study.

CONCLUSIONS:

This real-world analysis shows significantly lower annual medical costs and HCRU with semaglutide 2.4 mg versus no semaglutide 2.4 mg treatment in patients with ov/ob and ASCVD. Improving outcomes with semaglutide 2.4 mg combined with lower costs and HCRU may help slow the growing burden of ASCVD in this population.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes

Article

Author: Lübker, Christopher ; Lincoff, A. Michael ; Bøg, Martin ; Lingvay, Ildiko ; McEwan, Phil ; Toliver, Joshua C. ; Yeates, Florian ; Faurby, Mads ; Miller, Ryan ; Foos, Volker

AIMS:

The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D). We assessed cost-effectiveness of semaglutide 2.4 mg in this population against the American College of Cardiology/American Heart Association value framework.

MATERIALS AND METHODS:

A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed. Treatment costs were based on US list prices; scenario analyses used literature-reported estimated rebates. Healthcare costs and benefits were discounted at 3.0%. A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment. Subjects received either semaglutide 2.4 mg or placebo in addition to standard of care (SoC). Modelled outcomes included clinical events (CV events, progression to T2D, chronic kidney disease [CKD]) and health economic measures, including direct costs and quality-adjusted life years (QALYs).

RESULTS:

Mean semaglutide 2.4 mg treatment duration was 2.79 years. Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon. Average per-subject lifetime treatment costs were $47,353; savings arose from avoided T2D ($14,431), CKD ($2,074), and CV events ($1,512). Semaglutide 2.4 mg was associated with increased lifetime costs ($29,767), additional QALYs gained (0.218) and an incremental cost-effectiveness ratio of $136,271/QALY at list price; a scenario using an empirically estimated 48% rebate predicted $32,219/QALY.

LIMITATIONS:

The generalizability of observations from SELECT to a broader US population is unknown. Our model does not capture all outcomes nor costs that may be affected by weight loss. Modeling assumptions may present limitations.

CONCLUSIONS:

Semaglutide 2.4 mg use as in SELECT is cost-effective at list price, using a $150,000/QALY willingness-to-pay threshold.

01 Sep 2025·Obesity Pillars

Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea

Article

Author: Belarj, Soufiane ; Reyes, Anita ; Ziemke, Florencia ; Istfan, Nawfal ; Esguerra, Jem

Background:

Nausea is one of the most reported side effect of GLP-1 receptor agonists (GLP-1a). Current recommendations fall short in taming the symptoms, include antiemetic medication, behavior changes, GLP-1a dose adjustment, and often cause a disruption to treatment. Sea-Band® is a drug-free, class II FDA-cleared medical device for relief of nausea in motion sickness, morning sickness, chemotherapy and anesthesia induced nausea. The device is a set of soft, elastic, reusable acupressure wristbands (ACW) with a skin-facing plastic button worn below the wrist crease applying pressure at acupoint pericardium 6. We hypothesized that ACW was an effective tool for GLP-1a associated nausea.

Methods:

This was a one-arm, open-label, non-randomized, prospective interventional study evaluating the antiemetic effect of ACW in non-pregnant adults on GLP-1as with nausea. GLP-1a were semaglutide or tirzepatide. Exclusion criteria were patients on GLP-1a without nausea, recent use of antiemetic medications, other nausea-related conditions, history of gastroparesis, and uncontrolled gastroesophageal reflux disease. Patients were shown how to properly place and use ACW at the onset of nausea and were followed weekly for 4 weeks. Follow-ups assessed frequency of nausea, ACW use frequency and duration, and change in nausea.

Results:

359 episodes of nausea were recorded amongst 31 adult participants over 4 weeks. Adults, mean age 55, mean BMI 34, mean HbA1c 5.9 %, reported nausea over 80 % of the time on a weekly basis. ACW were used in all recorded episodes of nausea. Medication doses were kept stable throughout the duration of this study. Nausea relief was achieved within 5 min in one third of episodes, and in over 5 min but under 20 min in the remainder of the episodes. A logistic regression model was used to evaluate the likelihood of nausea relief. A consistent rate of nausea relief over 80 % was observed during the study period, adjusting for the correlation between reduced nausea episodes and reduced episodes.

Conclusion:

Although not a controlled trial, this pilot, proof of concept, pragmatic study suggests that ACW may offer a safe, self-administered, reusable, and drug-free option for managing GLP-1a associated nausea.ACW's nausea reducing effect was seen in over 80 % of episodes, and remained consistent throughout the study period. One third of participants experienced relief within 5 min of wearing ACW in the first three weeks. Given the relatively small sample size of the population, further large-scale investigations are justified. Nausea is common in day-to-day real-world use of GLP-1as, and our results suggest that using ACW may provide a first-line therapeutic intervention used ad libitum to tame a disruptive symptom, improve day-to-day well-being, and positively impact a person's treatment journey on GLP-1a.

2,213

News (Medical) associated with Semaglutide (Novo Nordisk)

18 Jul 2025

·www.prnewswire.com

Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Hims & Hers Health, Inc.(HIMS)

NEW YORK, July 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: HIMS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Hims was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;" (2) as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. WHAT'S NEXT? If you suffered a loss in Hims & Hers Health, Inc. during the relevant time frame, you have until August 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 SOURCE Levi & Korsinsky, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Patent Infringement

17 Jul 2025

·www.prnewswire.com

Weight Loss Drugs Like Ozempic May Help Prevent Stroke and Reduce Brain Injury-Related Complications, Studies Show

NASHVILLE, Tenn., July 17, 2025 /PRNewswire/ -- Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether. These medications, which lower blood sugar and often cause weight loss, are commonly prescribed for type 2 diabetes and obesity and include drugs like semaglutide (Ozempic). In the first study, "The Impact of Semaglutide (Ozempic) on Mortality and Survival in Patients with Acute Ischemic Stroke: A Nationwide and Institutional Retrospective Analysis," researchers at the University of Wisconsin–Madison used patient data from both the university's medical center and a global health collaborative to see whether patients on Ozempic who experienced strokes had better outcomes than patients not taking Ozempic. The global dataset included 2,021,704 patients who had experienced stroke, 43,338 of whom were also on Ozempic, and the University of Wisconsin dataset included 13,510 people who had experienced stroke, 190 of whom used Ozempic. Death from stroke was lower for Ozempic users across both cohorts. In the global dataset, 5.26% of Ozempic users initially died from their strokes compared to 21.61% of non-users, and Ozempic users also had a 77.5% chance of surviving their strokes long term compared to 30.95% of non-Ozempic users. The university cohort showed similar results, with 5.26% of Ozempic users dying from stroke versus 26.57% of patients not using Ozempic. In the second study, also from the University of Wisconsin–Madison, "Association between Ozempic Use and Stroke Risk: A Nationwide Emergency Department Analysis," researchers examined a large nationwide sample of emergency department records for people who experienced stroke and people who were likely using Ozempic. They found associations between potential Ozempic users and significantly reduced odds of stroke. The research team suggests taking this research further to evaluate data directly from pharmacies to be even more precise about the relationship between Ozempic and stroke prevention. The third study, "Impact Of GLP-1 Agonists on Stroke, SAH, and ICH: A Propensity-matched Multi-institutional Cohort Study," was presented by researchers from the University of Texas Medical Branch in Galveston. They investigated whether GLP-1 inhibitors could improve patient outcomes after brain hemorrhages (both spontaneous bleeds and those due to brain aneurysm rupture) and stroke. The team reviewed patient records from 6 months and 12 months after each brain hemorrhage and 1 year and 2 years after each stroke, finding that GLP-1 inhibitor use was connected to a reduced risk of cognitive side effects, seizures, future brain hemorrhage and death after brain hemorrhage and stroke. According to Ahmed Elbayomy, MD, a research fellow and data scientist in the Department of Neurological Surgery at the University of Wisconsin–Madison and primary author of two of these studies, these results are very promising. "More research is certainly needed, but seeing the potential protection offered by these medications is a fascinating finding." "This research could introduce a new perspective to the discussion of preventing and mitigating the devastating effects of stroke and related brain injuries," added Matias Costa, MD, from the Neurosurgery Department at the University of Texas Medical Branch and author of the third study. To receive a copy of these abstracts or to speak with the study authors, please contact Camille Jewell at [email protected] or call 202-248-5460. About the Society of NeuroInterventional Surgery The Society of NeuroInterventional Surgery (SNIS) is a scientific and educational association dedicated to advancing the specialty of neurointerventional surgery through research, standard-setting, and education and advocacy to provide the highest quality of patient care in diagnosing and treating diseases of the brain, spine, head and neck. Visit and follow us on X (@SNISinfo) Facebook (@SNISOnline), LinkedIn (@Society of NeuroInterventional Surgery), Instagram (@SNIS_info) and Bluesky (@snisinfo.bsky.social). SOURCE Society of NeuroInterventional Surgery WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

17 Jul 2025

·www.fiercepharma.com

Bristol Myers, Pfizer offer Eliquis at a discount through DTC online program

Bristol Myers Squibb and Pfizer have launched Eliquis 360 Support, a direct-to-patient online program, which offers the blood thinner to U.S. patients at a discount price. Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs directly to patients, Bristol Myers Squibb and Pfizer are doing the same with their megablockbuster blood thinner Eliquis.The drugmakers have established a direct-to-patient online program, Eliquis 360 Support, which offers the anticoagulant at a discount price to those in the United States who are uninsured, underinsured or pay for their drugs out of pocket.Eliquis will be available through the program at $346 per month, which is a 43% reduction from its list price of $606 per month. The new offering kicks off on Sept. 8.The effort targets a small group of current and potential users of Eliquis, as more than 90% of the patients on the pill access it through Medicare or with commercial insurance, according to BMS. Next year, when Inflation Reduction Act (IRA) pricing kicks in, Medicare will pay $231 per month for the treatment.“The BMS-Pfizer Alliance is committed to increasing patient access and affordability,” Chris Boerner, Ph.D., the CEO of BMS, said in a release. “This program passes more savings directly to patients and demonstrates our continued focus on identifying innovative solutions that foster the best outcomes for each individual while prioritizing access to care.”The initiative could attract more patients to the treatment and help soften the blow from generic competition. The company has told investors that it expects to lose patent protection in the U.S. for Eliquis in April of 2028. Sales reached $13.3 billion worldwide in 2024, with $9.6 billion coming in the U.S., where revenues were up 14%. BMS said that more than 15 million people in the U.S. have been prescribed Eliquis since it hit the market in 2012, resulting in an estimated $3 billion in total healthcare cost savings for every 100,000 patients treated. The medicine was originally approved to reduce the risk of stroke and blood clots in those who have an irregular heartbeat.Eliquis 360 Support also comes in response to President Donald Trump’s executive order, signed two months ago, which aims to slash the price of drugs in the U.S. through a most-favored-nations policy. While many questions remain about the initiative, Trump is instructing the Department of Health and Human Services (HHS) to tie what the government pays for drugs to the lowest prices paid by other economically advanced countries.Pfizer isn’t new to direct-to-patient marketing. Last year, it launched PfizerForAll, an online service that cut out middlemen, allowing patients to receive medicines, vaccines and diagnostic tests directly from the company. Early last year, Lilly established its online access program, LillyDirect, combining telehealth and pharmacy services to allow patients to receive the company’s diabetes, obesity and migraine treatments at a discount. Earlier this year, the company added Kisunla to its online program, allowing patients quicker access to the Alzheimer’s disease drug.In March of this year, Novo Nordisk launched NovoCare Pharmacy, offering obesity treatment Wegovy at $499 per month, which is a significant discount to its list price of $1,349.

Drug Approval

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonalcoholic Steatohepatitis	NDA/BLA	United States	Novo Nordisk A/S	30 Apr 2025
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03574597 (SELECT, Pubmed \| J Med Econ)	Phase 3	Cardiovascular Diseases \| Obesity	-	Semaglutide 2.4 mg	ivshnsrdfz(nodxhcyjwc) = sfurzomnxc mxjkxccxrg (otbjxcamey ) View more	Positive	31 Dec 2025
NCT05530577 (CTgov)	Phase 2	Nicotine Dependence	24	Semaglutide (Semaglutide)	ivwdxcucue(bztqciiduu) = fflbmtdvvj yceiclmxkk (hixnivxqsu, 0.63) View more	-	18 Jul 2025
				Sham/placebo (Sham/Placebo)	ivwdxcucue(bztqciiduu) = hpohmupidm yceiclmxkk (hixnivxqsu, 0.69) View more
NCT04560998 (STRIDE, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Peripheral Arterial Disease	792	Semaglutide	dmokbwatud(dzliaqvkjb) = mrnbfqqygr gfxcudbyfp (usbdvtqdga, ywvvbxggvb - vpqlxforfx) View more	-	08 Jul 2025
ACTRN12621001539820 (Pubmed) Manual	Phase 2	-	31	Semaglutide	zbqguoscco(lmsemgmyjh) = htwbusbsrz nxuugqrnyd (htmohglvwp, 0.90)	Positive	01 Jul 2025
				placebo	zbqguoscco(lmsemgmyjh) = bnkkougoek nxuugqrnyd (htmohglvwp, 0.93)
NCT06282458 (QUALITY, GlobeNewswire) Manual	Phase 2	Muscular Atrophy \| Obesity	148	Placebosemaglutide (after discontinuation of semaglutide; Day 112 to Day 196, ITT population)	unzyqwutbt(xgpcsqwzww) = mwwagollyf cnaiptmqoq (exphvpgwla, 0.40) View more	Positive	24 Jun 2025
				Enobosarm 3mgsemaglutide (after discontinuation of semaglutide; Day 112 to Day 196, ITT population)	unzyqwutbt(xgpcsqwzww) = wbigmskhka cnaiptmqoq (exphvpgwla, 0.40) View more
BELIEVE (NEWS) Manual	Phase 2	Overweight \| Obesity	507	Bimagrumab/Semaglutide	jctchciqop(qucrjnmzwu) = hcgsiwtkoa xlwtagvjbz (txyfbakkbb ) View more	Positive	23 Jun 2025
				Bimagrumab	jctchciqop(qucrjnmzwu) = pulwjetdvd xlwtagvjbz (txyfbakkbb ) View more
NCT05537233 (ADJUST-T1D, Pubmed \| NEJM Evid)	Phase 2	Diabetes Mellitus, Type 1 \| Obesity	72	Semaglutide up to 1 mg	ewlorsayxw(wzhmqmbimb) = shatrtxfcx xmcxeoycog (isagxjbwzz, -10.6 to -7.0) View more	Positive	23 Jun 2025
				Placebo	-
NCT05646706 (STEP UP, ADA2025 \| NEWS) Manual	Not Applicable	Obesity	1,407	semaglutide 7.2mg	oorrboqpvq(kppiiylrjy) = sugyzbnwbn msekkhrarh (vzjvxgyhva ) View more	Positive	20 Jun 2025
				semaglutide 2.4mg	oorrboqpvq(kppiiylrjy) = ngjmhcgihe msekkhrarh (vzjvxgyhva ) View more
NEWS Manual	Not Applicable	Obesity	-	Semaglutide/Tirzepatide	ilorsvfhvh(anpnpbzjzy) = fmwnsolwsw myngmhlazy (korgkclfqa ) View more	-	10 Jun 2025
NCT04822181 (Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis, Pubmed \| N Engl J Med)	Phase 3	Nonalcoholic Steatohepatitis	1,197	Semaglutide 2.4 mg	xelevysiwk(egfnussiep) = feaatycvcg mzmtjsqikn (gwwwylbcyn, 7.5 - 21.3) View more	Positive	05 Jun 2025
				Placebo	xelevysiwk(egfnussiep) = ohncsblvzn mzmtjsqikn (gwwwylbcyn ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis